home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

Webinar On U.S. FDA's Strategic Priorities - 2015 and Beyond

 
  December 02, 2014  
     
 


Compliance Trainings, Canada
2015-01-21


This webinar will discuss about two “Strategic Priorities” that the FDA has published to emphasize their future directions vis a vis regulated industry and public safety.

Each year companies are to perform a complete review of their quality management system and its ability to meet the current GMP's. The FDA has added a "Strategic Priorities" initiative that can assist companies to proactively address areas of GMP concern -- there are now two such reports – we will discuss both, emphasizing the latest “draft for public comment”, for 2014 - 2018. The reports reflect a major shift in the emphasis of the U.S. FDA cGMP compliance audits, clinical trial expectations, product submissions and company response requirements. In short, all regulatory areas are under evaluation by the FDA, and need to be revisited by a company's QA/RA and its senior management / staff.

This change in focus has a major impact on interpretation of individual compliance objectives, cGMP objectives, and measurements of success.  Ongoing negative publicity on pharmaceuticals, devices, as well as events in unrelated industries show many senior executives just don't get it, and have put pressure on the Agency to "get tough on compliance / enforcement".

This webinar will trigger such a response by an examination / review of FDA's stated concerns for corporate cGMP compliance and public safety.

Areas Covered in the Session :

Major “Drivers” and New U.S. FDA Initiatives

The FDA’s “Strategic Priorities” (1):  2011 – 2014

The FDA’s “Strategic Priorities” (2):  2014 – 2018

Major foreseeable problem areas for 2015 and beyond

Device, Pharmaceutical, Biological and Combination Products Issues

cGMP Issues - Strengthened Compliance

The Global Supply Chain

FDA's Life Cycle Requirements

Navigating through "Better Science"

A company gap analysis vis a vis FDA priorities

Correcting problem-prone areas

Interactive Q & A session

Who Will Benefit:

This webinar will provide valuable assistance to all U. S. FDA-regulated companies. It will assist in their reviewing and modifying their regulatory compliance stance in view of the areas the FDA indicates are of growing / future interest / emphasis. Its principles apply to personnel / companies in the Medical Devices, Pharmaceutical, Diagnostic, and Biologics fields. The employees who will benefit include:

Research & Development

Engineering Staff

Software Department

Quality Assurance

Regulatory Affairs

Manufacturing

Operations

cGMP instructors

Consultants

Mid-level and Senior Management

Personnel involved in verification and/or validation

Personnel involved in planning, execution and documentation

Price Tags:

Live

Single Live : For One Participant

$ 249

Corporate Live : For Max. 10 Participants

$ 899

Recording

Single REC : For One Participant - Unlimited Access for 6 Months

$ 299

For more information and enquiries contact us at

Compliance Trainings

5939 Candlebrook Ct, Mississauga, ON L5V 2V5, Canada 
Customer Support : #416-915-4458 
Email : support@compliancetrainings.com

 
 
Organized by: Compliance Trainings
Invited Speakers:

John E. Lincoln is a medical device and regulatory affairs consultant. He has helped companies to implement or modify their GMP systems and procedures, product risk management, U.S. FDA responses. In addition, he has successfully designed, written and run all types of process, equipment and software qualifications/validations, which have passed FDA audit or submission scrutiny, and described in peer-reviewed technical articles, and workshops, world wide. John has also managed pilot production, regulatory affairs, product development/design control, 510(k) submissions, risk management per ISO 14971, and projects; with over 28 years of experience in the FDA-regulated medical products industry - working with start-ups to Fortune 100 companies, including Abbott Laboratories, Hospira, Tyco/Mallinckrodt. He is a graduate of UCLA.

 
Deadline for Abstracts: 2015-01-21
 
Registration:

https://compliancetrainings.com/siteengine/Login.aspx

E-mail: suzzane.d@compliancetrainings.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.